Palvella reports Phase 2 TOIVA data: 100% bleed improvement, p=0.003

PALVELLA THERAPEUTICS, INC.

100% of patients with bleeding at baseline showed statistically significant improvement on cVM-IGA Bleeding at Week 12 (mean +2.5, p=0.003).
All bleeding patients reported 'satisfied' or 'very satisfied' with QTORIN rapamycin on Treatment Satisfaction Questionnaire at Week 12.
Baseline patient interviews show QoL burden includes pain, physical limitations, emotional distress from lesion visibility.
QTORIN rapamycin could become first FDA-approved therapy for cutaneous venous malformations, targeting >75,000 U.S. patients.
Data presented at 83rd SID Annual Meeting in Chicago on May 15, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.